Headlands Technologies LLC Invests $81,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 3,212 shares of the biopharmaceutical company’s stock, valued at approximately $81,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares during the last quarter. KBC Group NV grew its position in Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC increased its stake in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth $273,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Celldex Therapeutics during the fourth quarter valued at $306,000.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $15.78 on Monday. The stock’s 50-day moving average is $21.18 and its 200 day moving average is $25.33. Celldex Therapeutics, Inc. has a 1-year low of $15.46 and a 1-year high of $47.00. The company has a market cap of $1.05 billion, a P/E ratio of -6.14 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $1.25 million. On average, analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analysts Set New Price Targets

CLDX has been the topic of several recent analyst reports. The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.